Literature DB >> 21960891

Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group.

Miles P Sparrow, Peter M Irving, Leonard Baidoo, Brian Bressler, Adam S Cheifetz, Shane M Devlin, Laura E Harrell, Jennifer Jones, Patricia L Kozuch, Gil Y Melmed, Fernando S Velayos, Corey A Siegel.   

Abstract

In March 2008, a roundtable discussion was convened by the inflammatory bowel disease (IBD) specialist panel the BRIDGe (Building Resources and Research in IBD Globally) group, which consists of junior faculty gastroenterologists who have undergone advanced fellowship training at IBD referral centers in the United States, Canada, the United Kingdom, and Australia. An agenda was formulated to discuss three current controversies in Crohn's disease management: the role of 5-aminosalicylates, the use of biologic combination therapy versus monotherapy, and the use of step-up therapy versus top-down therapy for Crohn's disease. The aim of the meeting was three-fold: to review the data pertaining to each topic; to collect opinions from the participants as to their analysis of the literature and their current practice; and, where possible, to formulate recommendations of current best practice given the available evidence. This manuscript summarizes the discussions on these three areas of controversy in the current management of Crohn's disease.

Entities:  

Keywords:  5-aminosalicylates; Crohn's disease; Inflammatory bowel disease; biologic therapies; immunomodulators

Year:  2008        PMID: 21960891      PMCID: PMC3104182     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  29 in total

1.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

2.  Risk factors for colorectal cancer in Crohn's colitis: a case-control study.

Authors:  Corey A Siegel; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2006-06       Impact factor: 5.325

3.  Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study.

Authors:  Frank L Wolters; Maurice G Russel; Jildou Sijbrandij; Leo J Schouten; Selwyn Odes; Lene Riis; Pia Munkholm; Ebbe Langholz; Paolo Bodini; Colm O'Morain; Kostas Katsanos; Epameinondas Tsianos; Severine Vermeire; Gilbert Van Zeijl; Charles Limonard; Ole Hoie; Morten Vatn; Bjørn Moum; Reinhold W Stockbrügger
Journal:  Scand J Gastroenterol Suppl       Date:  2006

4.  National Cooperative Crohn's Disease Study: results of drug treatment.

Authors:  R W Summers; D M Switz; J T Sessions; J M Becktel; W R Best; F Kern; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

5.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Authors:  Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Donny M Chen; Michelle L Pritchard; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05       Impact factor: 11.382

6.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.

Authors:  J W Singleton; S B Hanauer; G L Gitnick; M A Peppercorn; M G Robinson; L D Wruble; E L Krawitt
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

7.  Predictors of Crohn's disease.

Authors:  Laurent Beaugerie; Philippe Seksik; Isabelle Nion-Larmurier; Jean-Pierre Gendre; Jacques Cosnes
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

8.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.

Authors:  Kathrine Frey Frøslie; Jørgen Jahnsen; Bjørn A Moum; Morten H Vatn
Journal:  Gastroenterology       Date:  2007-06-02       Impact factor: 22.682

9.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors:  R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal:  Arthritis Rheum       Date:  1998-09

10.  Maintenance therapy with certolizumab pegol for Crohn's disease.

Authors:  Stefan Schreiber; Mani Khaliq-Kareemi; Ian C Lawrance; Ole Østergaard Thomsen; Stephen B Hanauer; Juliet McColm; Ralph Bloomfield; William J Sandborn
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.